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of 17-desacetyl norgestimate following a single oral administration of a norgestimate and ethinyl estradiol
0.250 mg/0.035 mg tablets in 35 healthy female volunteers.
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an Jiaotong University.1. Introduction
17-desacetyl norgestimate is a metabolite of norgestimate (NGM).
Norgestimate [(17R)-17-(acetyloxy)-13-ethyl-18, 19-dinor-17-
pregn-4-en-20-yn-3-one oxime] is a synthetic progestationalier B.V. All rights reserved.
A. Saxena et al.94hormonal contraceptive, which regulates ovulation and menstrua-
tion [1–6]. Amongst the most commonly used oral contraceptives
are the combination types that contain both a synthetic estrogen
(ethinyl estradiol) and a synthetic progestin (norgestimate). Nor-
gestimate and ethinyl estradiol are well absorbed following oral
administration. These oral contraceptives hormones are metabo-
lized by the hepatic enzyme cytochrome P450 3A4 (CYP3A4) [7–
9]. NGM is metabolized to two active metabolites: its active
metabolites 17-desacetyl norgestimate [DesAc-NGM] and norges-
trel [NG]. The rapidity and completeness of these reactions mean
that circulating concentrations of NGM are extremely low and
probably contribute little to activity. On the average, peak serum
concentrations of norgestimate are observed within two hours
(0.5–2 h for norgestimate) after administration followed by a rapid
decline due to distribution and elimination. As the norgestimate
serum concentrations following single or multiple dosing are
generally below assay detection within 5 h, a major norgestimate
serum metabolite, 17-desacetyl norgestimate (which exhibits a
serum half-life ranging from 12 and 30 h), appears rapidly in
serum with concentrations greatly exceeding that of norgestimate.
The 17-deacetylated metabolite (pka 12.22) is pharmacologically
active and the pharmacologic proﬁle is similar to that of
norgestimate [10–14].
Reported literature has mentioned, to assess the effect of
anticonvulsants [8] and rosuavastatin [10], the pharmacokinetics
of 17-desacetyl norgestimate and plasma was analyzed for 17-
desacetyl norgestimate with validated LC–MS/MS method, but
analytical method details are not available for monitoring plasma
levels. Only pharmacodynamic properties are available in most of
the literature. So for monitoring of 17-desacetyl norgestimate
pharmacokinetics in clinical trials and bioequivalence/bioavaila-
bilty study, it was necessary to develop a simple, speciﬁc, rapid,
selective and sensitive analytical method for the quantiﬁcation of
17-desacetyl norgestimate in human plasma.
The only LC–MS/MS method reported by Wong et al. [15]
was used for determination of 17-desacetyl norgestimate requir-
ing 1 mL serum with double extraction with a large amount of
solvent consumption, double centrifugation and evaporation
steps. The total mentioned run time was 10.5 min with an
injection volume of 70 mL with less sensitivity ranging from
0.1 to 5 ng/mL. As the described method was cumbersome and
with the given time and speed challenges for a typical BA/BE
turnaround timelines, it was felt necessary to develop a simple,
rapid and sensitive analytical method for the quantiﬁcation of 17-
desacetyl norgestimate.
This paper describes the development and validation of an LC–
MS/MS method for the quantiﬁcation of 17-desacetyl norgestimate
in human plasma having reduced analytical run time with a lower
limit of quantiﬁcation (LOQ) 20.221 pg/mL.2. Experimental
2.1. Chemicals and reagents
The analytical standards of 17-desacetyl norgestimate and 17-
desacetyl norgestimate D6 were obtained from Clearsynth (Mum-
bai, India). High-purity water was prepared in-house using a Milli-
Q water puriﬁcation system obtained from Millipore (Bangalore,
India). Gradient grade methanol and acetonitrile were purchased
from Merck (Darmstadt, Germany). LC/MS-grade formic acid was
purchased from Fisher scientiﬁc (Geel, Belgium). Drug-free(blank) buffered human plasma was obtained from Drug Monitor-
ing Research Institute (Mumbai, India) and was stored at 20 1C
prior to use.
2.2. Calibration curves
Stock solutions of 17-desacetyl norgestimate and internal standard,
17-desacetyl norgestimate D6, were prepared in methanol at a
concentration of 250 mg/mL and 100 mg/mL, respectively. Sec-
ondary and working standard solutions were prepared from stock
solutions by dilution with methanol/water (50/50, v/v) using a
serial dilution method. These diluted working standard solutions
were used to prepare the calibration curve and quality control (QC)
samples in human plasma.
A ten-point standard calibration curve for 17-desacetyl
norgestimate was prepared by spiking 2% of 17-desacetyl
norgestimate working standard solution in the blank plasma.
The calibration curve ranged from 20.221 to 5002.914 pg/mL.
Quality control samples were prepared at four concentration
levels—20.221 pg/mL for Lower Limit of Quantiﬁcation
Quality Control (LLOQQC), 60.085 pg/mL for Low Quality
Control (LQC), 2036.767 pg/mL for Medium Quality Control
(MQC) and 3916.860 pg/mL for High Quality Control
(HQC) samples for 17-desacetyl norgestimate from the stock
solutions.
2.3. Sample preparation
A 0.5 mL aliquot of 17-desacetyl norgestimate spiked on human
plasma sample was mixed with 50 mL of internal standard working
solution equivalent to 60 ng/mL of 17-desacetyl norgestimate D6.
Then, 0.5 mL of 1% formic acid was added and vortexed to mix.
The sample mixture was loaded into an Oasis HLB (1 cm3/30 mg),
extraction cartridge that was preconditioned with 1.0 mL methanol
followed by 1.0 mL water. The extraction cartridge was washed
with 1.0 mL water followed by 1.0 mL of 20% acetonitrile in water.
Both 17-desacetyl norgestimate and 17-desacetyl norgestimate D6
were eluted with 1 mL of methanol; 10 mL of the sample was
injected into the LC–MS/MS system.
2.4. Instrumentation
Chromatographic separation was carried out on Waters UPLC
with Zorbax Eclipse XDB-C18 (150 mm 4.6 mm, 5 mm) pur-
chased from Agilent, the United States. A degassed mobile
phase consisting of acetonitrile (A) and 0.1% formic acid in
water (B) was delivered with a ﬂow rate of 0.75 mL/min using a
time and solvent composition gradient. Each analytical run was
started at 50% A up to 0.3 min followed by a liner gradient to
90% A over 0.5 min, held at 90% A for 2.7 min, shifted to linear
to 50% A over 0.5 min, and then held constant until the end of
the run for column equilibration to take on the next analytical
run. The total run time for each sample analysis was 4.5 min.
The column oven temperature was kept at 40 1C. Mass spectra
were obtained using an Xevo TQ-S mass spectrometer, a triple-
stage quadrapole-mass-analyzer with photomultiplier detector
equipped with electrospray ionization (ESI) source (Waters
Ltd., UK) running on positive ion mode. The mass spectrometer
was operated in the multiple reaction-monitoring (MRM) scan
mode. The data acquisition was ascertained by MassLynx 4.1
software.
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The method was validated for speciﬁcity, selectivity, sensitivity,
linearity, precision, accuracy, recovery, stability and matrix effect
meeting the global regulatory requirements [16,17]. Speciﬁcity
was performed by analyzing human female blank plasma samples
from different sources (or donors) to test for interference at the
retention time of 17-desacetyl norgestimate and internal standard,
17-desacetyl norgestimate D6. Selectivity was performed by
spiking concomitant drugs like ranitidine, paracetamol, ibuprofen
and aspirin. The plasma samples were then processed and analyzed
to investigate possible interference. Sensitivity was determined by
analyzing six replicates of blank human plasma spiked with the
analyte at the lowest level of the calibration curve. The intra-run
and inter-run accuracy were determined by replicate (n¼6)
analysis of three quality control samples and at LOQ that were
extracted from the sample batch. The intra-run (within batch)
precision and accuracy were evaluated by analysis of six replicates
at four concentrations in a same analytical run. The inter-run
precision and accuracy of the calibration standards were assessed
using ﬁve calibration curves used for assay validation. The inter-
run (between-batch) precision and accuracy were evaluated after
repeated analysis in ﬁve different analytical runs in different days
and on different instrument.
Accuracy was deﬁned as the percent of relative error (RE) and was
calculated using the formula RE (%)¼ðETÞ  ð100=TÞ, where E
is the experimentally determined concentration and T is the theoretical
concentration. Assay precision was calculated by using the formula
RSD (%)¼ðSD=MÞ  100, where RSD is the relative standard
deviation, M is the mean of experimentally determined concentra-
tions, and SD is the standard deviation of M.
The extraction efﬁciencies of 17-desacetyl norgestimate and
17-desacetyl norgestimate D6 were determined by comparing the
peak area of extracted analytes to the peak area of non-extracted
standards (analyte spiked post extraction in blank plasma).
The processed sample stability was evaluated by comparing the
freshly extracted plasma samples which were injected immediately
(time 0), with the samples that were re-injected after kept in the
autosampler at 10 1C for a speciﬁc duration of time. The stability
of spiked human plasma stored at room temperature (bench-top
stability) was evaluated by comparing the mean of back-calculated
concentrations of the samples kept on bench with freshly prepared
extracted samples. The freeze–thaw stability was conducted by
comparing the stability samples that had been frozen and thawed
ﬁve times stored at 30 and 75 1C, with freshly spiked quality
control samples. The long-term stability of spiked human plasma
was evaluated by analyzing low-, medium- and high-quality
control samples that were stored at 30 and 75 1C for a long
duration together with freshly spiked calibration standard and
quality control samples. Stability was determined by calculating
the change and was calculated using the formula Change ð%Þ ¼
ðSCÞ  100=C, where S is the mean stability sample concentra-
tion and C is the mean freshly prepared or comparison sample
concentration. Analytes were considered stable if the Change was
within 715% of the freshly prepared or comparison sample.
Matrix effect was evaluated with eight different lots of plasma
containing K3EDTA as anticoagulant including one hemolysed lot
and one lipemic plasma lot. Three post-spiked samples at each of
LQC, MQC and HQC levels were prepared from different lots of
plasma (in total 24 samples). Aqueous (unextracted derivatized)
spiked samples for 17-desacetyl norgestimate and 17-desacetyl
norgestimate D6 at LQC, MQC and HQC levels were prepared inelution solution considering zero matrix effect. The post-spiked
extracted LQC, MQC and HQC samples along with six replicate
injections of aqueous un-extracted samples at LQC, MQC and
HQC levels were analyzed. The matrix effect was evaluated by
calculating the matrix factor for area response of 17-desacetyl
norgestimate and 17-desacetyl norgestimate D6 and IS normalized
matrix factor for mean area ratio of 17-desacetyl norgestimate and
17-desacetyl norgestimate D6.
This was performed with the aim to observe the matrix effect of
these different lots of plasma on the %RSD of mean matrix factor
for analyte area, IS area and IS normalized area ratio. It was
considered there was no matrix effect if the %RSD for mean
matrix factor was less than 15% at each level for analyte area, IS
area and IS normalized area ratio.3. Results and discussion
3.1. Tuning and chromatography optimization
To develop a rapid, selective, sensitive and simple assay method for the
extraction and quantiﬁcation of 17-desacetyl norgestimate during
method development, different options were evaluated to optimize
extraction, chromatography separation and MS detection parameters.
The extraction was ﬁrst tried by precipitating the proteins in spiked
plasma like acetonitrile, methanol and acidic methanol. Further, trials
were taken by liquid-liquid extraction with traditional protocol using
ethyl acetate, diethyl ether, t-butyl methyl ether and a combination of
ethyl acetate and dichloromethane. The recoveries obtained were low
but consistent; however, the response for LOQ was not quantiﬁable
and there was signiﬁcant interference observed from the plasma
matrix. After the use of different SPE cartridges, a thorough sample
cleanup could be achieved by using Hydrophillic–Lipophillic
balanced (HLB) reverse-phase cartridges. The extraction methodol-
ogy had ensured a better recovery with no matrix effect and no
interference was observed for both 17-desacetyl norgestimate and 17-
desacetyl norgestimate D6 analytes.
Further optimization in chromatography conditions resulted in
improvement in signal, base-line noise and reduced run time.
It was also observed that reduction in buffer pH resulted in
improved response and peak symmetry. Use of Zorbax Eclipse
XDB-C18 (150 mm 4.6 mm, 5 mm) column enabled use of high
ﬂow rate, which resulted in run time as low as 4.5 min with better
peak symmetry and signal of analytes. The optimized detection
and sample extraction chromatography were enabled to reduce
processing and analysis time without compromising the sensitivity.
Electro spray ionization (ESI) and atmospheric pressure chemical
ionization (APCI) were evaluated to obtain better response of
17-desacetyl norgestimate which accepted the proton in an acidic
mobile phase and produced a protonated precursor ion ([MþH]þ) at m/
z 328.4. It was found that the best signal was achieved with ESI
positive ion mode. Product ion m/z 328.4 of 17-desacetyl norgestimate
was monitored, which gave better sensitivity and selectivity. The ﬁnal
MRM parameters of 17-desacetyl norgestimate and its internal standard
were set at m/z 328.4/124.1 and 334.3/91.1, respectively. The selected
fragment ions of each compound, as product ion to be monitored, are
indicated in Fig. 1.
3.2. Speciﬁcity
Utilization of predominant product ions for each compound
enhanced the mass spectrometric speciﬁcity. The mass transition
Fig. 1 ESI product ion mass spectra of the precursor ions of (A) 17-desacetyl norgestimate and (B) 17-desacetyl norgestimate D6.
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mate and 334.3-91.1 for 17-desacetyl norgestimate D6. The
product ions selected were speciﬁc for derivatized 17-desacetyl
norgestimate and 17-desacetyl norgestimate D6, respectively.
Chromatographic speciﬁcity of the method was demonstrated by the
absence of endogenous interfering peaks at retention times of 17-
desacetyl norgestimate and its internal standard in 10 different lots of
extracted blank plasma including one haemolysed and one lipemic
plasma. Representative chromatograms of extracted blank plasma and
extracted plasma samples containing 20.221 pg/mL 17-desacetyl
norgestimate (low standard) are presented in Fig. 2.3.3. Linearity
The peak area ratios (area of 17-desacetyl norgestimate/area of
17-desacetyl norgestimate D6) of calibration standards were
proportional to the concentration of analytes in each assay over
the nominal concentration range of 20.221–5002.914 pg/mL for
17-desacetyl norgestimate. The calibration curves were found to be
linear and were well described by least squares lines. A weighting
factor of 1/concentration2 was chosen to achieve homogeneity of
variance. The correlation coefﬁcients were Z0.9988 (n¼5) for17-desacetyl norgestimate. The mean (7SD) slopes of the
calibration curves (n¼5) for 17-desacetyl norgestimate were
0.000933037 (70.0000460). The mean accuracy and precision
for back-calculated concentrations of each standard calculated
from calibration curve are tabulated in Table 1.
3.4. Sensitivity (lower limit of quantiﬁcation)
The LOQ is deﬁned as the lowest concentration of the calibration
standard yielding accuracy 720% and precision of r20%. The
LOQ for 17-desacetyl norgestimate was 20.221 pg/mL. These data
are tabulated in Table 2. The intra-run precision at the LOQ
plasma samples containing 17-desacetyl norgestimate was 1.62%.
The intra-run accuracy (%RE) at the LOQ plasma samples
containing 17-desacetyl norgestimate was 3.76%.
3.5. Precision and accuracy
The intra-run precision was r5.02% and intra-run accuracy was
r3.76 for 17-desacetyl norgestimate (Table 2). The inter-run
precision and accuracy were determined by pooling all individual
assay results of replicate (n¼6) QC samples over the ﬁve separate
Fig. 2 Representative chromatograms of (A) extracted blank plasma sample and (B) extracted plasma LLOQ sample.
Table 1 Calibration curve back-calculated concentrations of 17-desacetyl norgestimate (n¼5).
Standard conc. (pg/mL) Mean calculated conc. 7SD (pg/mL) RSD (%) RE (%) Slope Intercept Correlation coefﬁcient (r)
20.221 21.03470.516 2.45 4.02 0.000933037 0.00026 0.9988
40.442 37.48971.764 4.71 7.30
128.388 123.53976.529 5.28 3.78
256.775 261.107710.713 4.10 1.69
513.55 518.50074.367 0.84 0.96
1027.101 1051.524722.360 2.13 2.38
2054.202 2071.613749.958 2.41 0.85
3020.885 2935.2827148.255 5.05 2.83
4027.846 4031.551771.350 1.77 0.09
5002.914 5199.1197356.318 6.85 3.92
Table 2 Intra-run (within-batch) and inter-run (between-batch) precision and accuracy of 17-desacetyl norgestimate in human plasma
(n¼6).
Spiked conc. (pg/mL) Intra-run precision and accuracy Inter-run precision and accuracy
Mean calculated conc. 7SD (pg/mL) RSD (%) RE (%) Mean calculated conc. 7SD (pg/mL) RSD (%) RE (%)
20.221 20.98170.339 1.62 3.76 20.47171.245 6.08 1.24
60.085 57.64772.896 5.02 4.06 58.59373.660 6.25 2.48
2036.767 2064.948721.480 1.04 1.38 2048.910758.157 2.84 0.60
3916.860 3822.5827168.806 4.42 2.41 3886.1957158.228 4.07 0.78
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Fig. 3 Mean 17-desacetyl norgestimate plasma concentration–time
proﬁle following a 0.250 mg oral dose of norgestimate in human subjects.
A. Saxena et al.98batch runs. The inter-run precision was r6.25. The inter-run
accuracy was r1.24 for 17-desacetyl norgestimate (Table 2).
3.6. Recovery
Six replicates at low-, medium- and high-quality control concen-
trations for 17-desacetyl norgestimate were prepared for recovery
determination. The mean recovery for 17-desacetyl norgestimate
was 96.30% with precision of 5.47%. The mean recovery for 17-
desacetyl norgestimate D6 was 93.90%.
3.7. Stability
The results of the stability studies are enumerated in Table 3. The
bench-top stability, process stability, freeze–thaw stability and
long-term stability in matrix of 17-desacetyl norgestimate in
plasma were investigated by analyzing quality control samples inTable 3 Stability results for 17-desacetyl norgestimate (n¼6).
Stability Spiked conc.
(pg/mL)
Mean comparison sample conc. 7SD
(pg/mL)
Processa 60.085 57.19271.812
2036.767 2020.348732.45
3916.86 3785.0337183.483
Bench-topb 60.085 57.19271.812
2036.767 2020.348732.450
3916.86 3785.0337183.483
Freeze-thawc 60.085 57.13870.792
2036.767 1959.26479.407
3916.86 3769.177728.333
Freeze-thawd 60.085 57.13870.792
2036.767 1959.26479.407
3916.86 3769.177728.333
Long-terme 60.085 61.68770.411
2036.767 2102.625711.277
3916.86 4005.311745.027
Long-termf 60.085 61.68770.411
2036.767 2102.625711.277
3916.86 4005.311745.027
aAfter 60 h in autosampler at 10 1C.
bAfter 6 h at room temperature
cAfter four freeze-thaw cycles at –30 1C.
dAfter four freeze-thaw cycles at –75 1C.
e
–30 1C for 116 days.
f
–75 1C for 116 days.
Table 4 Matrix effect for 17-desacetyl norgestimate and 17-desacet
Parameter LQC MQC
Mean matrix factor7SD RSD (%) Mean matrix
Analyte area 1.00170.055 5.49 0.77670.020
IS area 1.02970.036 3.50 0.82770.030
IS normalized 0.97270.038 3.91 0.93870.020replicates (n¼6) at LQC, MQC and HQC levels. Process stability
results indicated that the difference in back-calculated concentra-
tion from time 0 to 60 h was r3.44%, which allowed one toMean stability sample conc. 7SD
(pg/mL)
Change in stability (%)
59.15871.921 3.44
2051.73679.247 1.55
3914.9967102.645 3.43
55.48472.931 2.99
1987.116744.628 1.64
3934.411770.137 3.95
57.45370.522 0.55
1954.356717.848 –0.25
3740.842719.078 0.75
57.89170.352 1.32
1958.206717.378 0.05
3767.058727.159 0.06
61.11170.920 1.32
2109.83179.024 1.68
3970.363743.975 0.45
61.49670.507 0.70
2126.586717.402 2.48
3952.226719.215 0.01
yl norgestimate D6 (n¼8).
HQC
factor7SD RSD (%) Mean matrix factor7SD RSD (%)
2.58 0.84470.046 5.45
3.63 0.91970.028 3.25
2.13 0.91970.044 4.79
Table 5 Pharmacokinetic parameter.
Drug Statistics Cmax (pg/mL) tmax (h) AUC0 t (pg h/mL) AUC01 (pg h/mL) Kel (h
1) t1/2 (h)
Test (T) Mean 2289.2065 2.146 25,087.6725 28,025.4948 0.0230 31.896
SD 538.8891 0.818 4382.7754 5186.3281 0.0060 7.381
RSD (%) 23.54 38.14 17.47 18.51 26.10 23.14
Reference (R) Mean 1979.9418 2.143 23,667.5552 26,326.6297 0.0230 31.819
SD 454.1852 0.743 3868.6896 4031.8116 0.0054 7.832
RSD (%) 22.94 34.69 16.35 15.31 23.55 24.61
Cmax, the maximum plasma concentration.
tmax, the time to reach Cmax.
AUC0 t, the area under the plasma concentration–time curve from time zero to the last sampling time.
AUC01, the area under the plasma concentration–time curve from time zero to inﬁnity.
Kel, elimination rate constant.
t1/2, elimination half-life.
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10 1C in autosampler of the UPLC system. Results of bench-top
stability for 17-desacetyl norgestimate were found to be stable for
at least 6 h at room temperature in plasma samples. Freeze and
thaw stability results indicated that the repeated freezing–thawing
(four cycles) did not affect the stability of 17-desacetyl norgesti-
mate for samples stored at 30 and 75 1C temperatures. Long-
term stability of 17-desacetyl norgestimate in plasma was per-
formed at LQC, MQC and HQC levels and was found to be stable
for at least 116 days at 30 and 75 1C.
3.8. Matrix effect
The matrix factor for 17-desacetyl norgestimate and 17-desacetyl
norgestimate D6 was calculated by comparing the area response
for the analyte, IS and IS normalized area ratio observed in post-
spiked samples with that of unextracted derivatized samples at
LQC, MQC and HQC levels and the matrix effect was evaluated
from the %RSD of mean matrix factor at each level. Three quality
control samples at each level were analyzed and the %RSD of the
samples analyzed was found r5.49% for analyte area, IS area and
IS normalized area ratio for 17-desacetyl norgestimate and
17-desacetyl norgestimate D6 (Table 4).
Hence, this clearly proved that the elution of endogenous matrix
peaks during the run had no effect on the quantiﬁcation of
17-desacetyl norgestimate. Therefore, the method of extraction
of 17-desacetyl norgestimate from plasma was robust enough and
gave accurate and consistent results when applied to real subject
samples.
3.9. Application of method
The proposed validated method was applied for the determination
of 17-desacetyl norgestimate in plasma samples from ongoing
projects for the development of an oral contraceptive formulation.
Plasma samples were periodically collected up to 96 h after a
single oral dose administration of a norgestimate and ethinyl
estradiol 0.250 mg/0.035 mg tablet to 35 healthy female volunteers
in each phase. The time periods at which the plasma samples were
drawn were 0.00, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00,
8.00, 12.00, 24.00, 36.00, 48.00, 72.00 and 96.00 h after a single
oral dose administration. A total of 1120 human plasma samples
from 35 female volunteers were analyzed along with calibrationstandards and QC samples. Twelve calibration curves were made
for sample quantiﬁcation with forty-eight sets of interspersed
LQC, MQC and HQC samples. No signiﬁcant interference
peak was found in predose samples for all volunteers. The mean
(7SD) plasma maximum concentrations (Cmax) obtained for the
17-desacetyl norgestimate test and reference formulations were
2289.2065 (7538.8891) pg/mL and 1979.9418 (7454.1852) pg/
mL, respectively. The mean 17-desacetyl norgestimate plasma
concentration–time proﬁle following a 0.250 mg oral dose of
norgestimate under fasting conditions to human subjects is shown
in Fig. 3 and the pharmacokinetic data are presented in Table 5.4. Conclusions
A ﬁrst of its kind of analytical method using LC–MS/MS system
was developed for the determination of 17-desacetyl norgestimate in
human plasma. The described method was a simple, speciﬁc, rapid,
reproducible and sensitive method with an LOQ of 20 pg/mL for
17-desacetyl norgestimate.
It was concluded that this sensitive and speciﬁc method was
applicable for the quantitative determination of 17-desacetyl
norgestimate in human plasma in pharmacokinetic and bioavail-
ability studies of 17-desacetyl norgestimate.
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